General description
A cis-polyunsaturated fatty acid found in the plasma membrane. Major component of membrane phospholipids. Following its release by cellular phospholipases, it is enzymatically converted to a variety of inflammatory and vasoactive metabolites, such as prostaglandins (via the cyclooxygenase pathway), leukotrienes (via the lipoxygenase pathway), and epoxides (via the cytochrome P450 pathway). Binds to G-protein α-subunits in a covalent, posttranslational manner. Inhibits Ras-GAP. Stimulates the synthesis of nitric oxide by platelets.
Precursor for prostaglandins, prostacyclin, and thromboxane. Binds to G-protein α-subunits in a covalent, post-translational manner. Inhibits Ras-GAP. Stimulates the synthesis of nitric oxide by platelets. Modulates nitric oxide production by prostaglandin synthesis via the cyclooxygenase pathway.
Biochem/physiol Actions
Cell permeable: no
Primary Target
Ras-GAP
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Warning
Toxicity: Harmful (C)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Other Notes
Hallak, H., et al. 1994. J. Biol. Chem. 269, 4713.
Khurana, G., and Bennett, M.R. 1993. Br. J. Pharmacol. 109, 480.
Han, J.-W., et al. 1991. Science252, 576.
Radomski, M.W., et al. 1990. Br. J. Pharmacol. 101, 325.
Neddleman P., et al. 1986. Annu. Rev. Biochem.55, 69.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51286505
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 181198-100MG
